Levels of alpha-toxin correlate with distinct phenotypic response profiles of blood mononuclear cells and with agr background of community-associated Staphylococcus aureus isolates by Mairpady Shambat, S. (Srikanth) et al.
Levels of Alpha-Toxin Correlate with Distinct Phenotypic
Response Profiles of Blood Mononuclear Cells and with
agr Background of Community-Associated
Staphylococcus aureus Isolates
Srikanth Mairpady Shambat1, Axana Haggar1, Francois Vandenesch2, Gerard Lina2,
Willem J. B. van Wamel3, Gayathri Arakere4, Mattias Svensson1, Anna Norrby-Teglund1*
1 Karolinska Institutet, Centre for Infectious Medicine, Stockholm, Sweden, 2CIRI, International Center for Infectiology Research, LabEx Ecofect, Universite´ Lyon 1, Inserm
U1111, Ecole Normale Supe´rieure de Lyon, CNRS UMR5308, Centre National de Re´fe´rence des Staphylocoques, Hospices civils de Lyon, Lyon, France, 3Department of
Medical Microbiology and Infectious Diseases, Erasmus Medical Centre, Rotterdam, Netherlands, 4 Society for Innovation and Development, Indian Institute of Science
Campus, Bangalore, India
Abstract
Epidemiological studies of Staphylococcus aureus have shown a relation between certain clones and the presence of specific
virulence genes, but how this translates into virulence-associated functional responses is not fully elucidated. Here we
addressed this issue by analyses of community-acquired S. aureus strains characterized with respect to antibiotic resistance,
ST types, agr types, and virulence gene profiles. Supernatants containing exotoxins were prepared from overnight bacterial
cultures, and tested in proliferation assays using human peripheral blood mononuclear cells (PBMC). The strains displayed
stable phenotypic response profiles, defined by either a proliferative or cytotoxic response. Although, virtually all strains
elicited superantigen-mediated proliferative responses, the strains with a cytotoxic profile induced proliferation only in
cultures with the most diluted supernatants. This indicated that the superantigen-response was masked by a cytotoxic
effect which was also confirmed by flow cytometry analysis. The cytotoxic supernatants contained significantly higher levels
of a-toxin than did the proliferative supernatants. Addition of a-toxin to supernatants characterized as proliferative switched
the response into cytotoxic profiles. In contrast, no effect of Panton Valentine Leukocidin, d-toxin or phenol soluble modulin
a-3 was noted in the proliferative assay. Furthermore, a significant association between agr type and phenotypic profile was
found, where agrII and agrIII strains had predominantly a proliferative profile whereas agrI and IV strains had a
predominantly cytotoxic profile. The differential response profiles associated with specific S. aureus strains with varying
toxin production could possibly have an impact on disease manifestations, and as such may reflect specific pathotypes.
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Introduction
Staphylococcus aureus (S. aureus) is a significant cause of human
infections and an emerging health problem globally due to its
increasing resistance to beta-lactams (methicillin-resistant S.
aureus, MRSA). A special cause of concern is the rise in
community-acquired (CA) S. aureus strains, and particularly
concerning are reports of specific CA-MRSA clones associated
with highly aggressive infections, including necrotizing fasciitis and
pneumonia in otherwise healthy individuals [1–3]. Although there
are large geographical differences, epidemiological studies have
shown that more than 20 distinct CA-MRSA lineages are present
globally [4].
The pathogenesis of invasive staphylococcal infections involves
a variety of virulence factors. In severe invasive infections, several
exotoxins have been implicated in disease pathogenesis, such as
superantigens [5–7], as well as the cytotoxins Panton Valentine
Leukocidin (PVL) [8–10], alpha-toxin (a-toxin) [8,10], and phenol
soluble modulins (PSMs) [10,11]. There are to date 24 distinct
superantigens identified in S. aureus, including the well charac-
terized TSST-1 and the staphylococcal enterotoxins (SE) A–C.
Superantigens have been attributed a central role in mediating the
systemic toxicity and shock by virtue of their ability to induce
hyper-inflammatory responses [6,7], and they have also been
implicated in severe pulmonary infections [5]. Cytotoxins have
been associated with cell and tissue injury as well as inflammation
PLOS ONE | www.plosone.org 1 August 2014 | Volume 9 | Issue 8 | e106107
in severe invasive infections, including necrotising infections of the
skin and lung [10]. Several of the toxins are encoded by mobile
genetic elements resulting in great diversity in toxin gene content
among S. aureus strains [12,13] Many of these virulence factors
are regulated and controlled by a global regulator system called
the accessory gene regulator (agr) system encoded by the agr locus
[14–17]. The agr locus has diverged among different S. aureus
strains with polymorphism in agrBDC region, resulting in four
major allelic types of agr, i.e. agrI–IV [15,17,18]. A recent study
demonstrated the impact of allelic variation on agr induction
dynamics, which translated into significant differences in expres-
sion of several virulence factors [19].
S. aureus infected patients have been shown to develop
antibodies against both superantigens and cytotoxins [20–24];
thus demonstrating that patients are exposed to a combination of
exotoxins secreted by the strains during infection. Exactly how
these different combinations of toxins affect virulence and disease
outcome is, as of yet, not fully elucidated. One example of
interactions between superantigens and cytotoxins was reported by
Broshnan et al [25] who showed that cytolysins promoted
increased penetrance of superantigens in mucosa. Here we set
out to explore how diversity in exotoxin profiles among CA S.
aureus strains translates into virulence-associated functional
responses. To this end, we determined the effect on peripheral
blood mononuclear cells (PBMC) elicited by CA S. aureus strains
of different sequence types (ST) with distinct agr allelic types and
toxin gene profiles. Our data revealed that the strains induced
differential responses in PBMC, characterized by either cytotoxic
or proliferative responses, which were linked to specific agr types
and levels of a-toxin expression.
Materials and Methods
Ethics Statement
This study includes blood samples from buffy coats of blood
provided by the blood bank at the Karolinska University Hospital.
The buffy coats were provided anonymously; hence informed
consent was not required. The ethical research committee at
Huddinge University Hospital (Forskningskommitte Syd) ap-
proved the study.
Clinical isolates
Strains (n = 38) were selected from a heterogeneous cohort of
CA S. aureus representing a diverse collection of isolates with
different ST and toxin profiles collected from colonized individuals
(nasal swabs) or patients with varying S. aureus infections in India
(Table 1). The isolate collection has previously been characterized
with respect to antibiotic resistance profile, molecular typing
including ST, agr-types, and toxin profile as determined by either
PCR for specific genes or by a DNA microarray covering 185 S.
aureus genes [26]. The study also included a confirmatory cohort
of 31 isolates collected from patients with CA S. aureus
pneumonia included in a prospective cohort study in France [9]
or from cases referred to the French national reference laboratory
for staphylococci.
A clinical USA300 strain (LUG2012) from a patient from
South-Ouest of France and its isogenic mutants deficient for either
a-toxin (LUG2209) or PVL (LUG2040) were also included to
confirm toxin-mediated effects. The deletion mutants were
obtained by using pMAD [27] carrying the replacement cassette
that was electroporated to RN4220 recipient strain and then to
LUG2012. Growth at non-permissive temperature (44uC) was
followed by several subcultures at 30uC and 37uC to favor double
crossing over as previously described [28]. Validation of deletion
of the hla (LUG2209) or lukSF-PV (LUG2040) genes were done
by PCR and the production of a-toxin and PVL were determined
with previously described toxin-specific ELISA (see below).
Preparation of bacterial culture supernatants
The strains were cultured overnight at 37uC in 25 ml casein
hydrolysate and yeast extract (CCY) medium. Cell-free superna-
tants were prepared through centrifugation at 3350 g followed by
filter sterilization.
Toxin determination
Bacterial supernatants were assessed for the presence of selected
exotoxins, including a-toxin, staphylococcal enterotoxin B (SEB),
and toxic shock syndrome toxin 1 (TSST-1), using a multiplex
competition immunoassay based on Luminex technology [29],
and the amounts of a-toxin and PVL in the bacterial supernatants
were determined by specific ELISA as previously described
[30,31] using specific antibodies kindly provided, respectively, by
GSK Biologicals Inc. (USA) and bioMerieux R&D Immunodiag-
nostic (France).
PBMC proliferation assay
Human PBMC were isolated from healthy donors using
Lymphoprep density centrifugation. The cells were cultured in
RPMI-1640 medium supplemented with 10% FCS, 10 mM of L-
glutamine, Penicillin (100 U/ml)/Streptomycin (100mg/ml) and
25 mmol/L HEPES (all from Thermo Scientific HyClone, USA).
PBMC were seeded at 26105 cells/well and stimulated at 37uC
with serial dilutions of bacterial supernatants. After 72 hours, the
cells were pulsed for 6 hours with 1 mCi/well of 3H-thymidine
(Perkin-Elmer) after which 3H-uptake was measured in a beta-
scintillation counter. Phytohemagglutinin-L (PHA) (1 mg/ml)
(Sigma-Aldrich, St. Louis, USA) was used as a positive control
for polyclonal T cell activation. The cytotoxic/inhibitory effect
was tested by the addition of bacterial supernatants in combination
with PHA in the proliferation assay. The bacterial culture medium
CCY was included as a negative control, and was found to have
negligible effect on proliferation (mean CPM 3088, 1785, 1719 for
1:50; 1:100 and 1:1000 dilution, resp.) and no inhibitory effect on
PHA-induced proliferation. PBMC were also stimulated with
bacterial supernatants or PHA in combination with purified a-
toxin (Sigma-Aldrich, St. Louis, USA), recombinant PVL,
recombinant d-toxin and purified PSM-a3 (all from IBT
Bioservices, Gaithersburg, USA) and proliferation assessed.
IVIG inhibition assay
PBMC were stimulated with bacterial supernatants, a-toxin or
PHA in the presence or absence of different concentrations of
IVIG (Gammagard S/D, Baxter). Proliferative responses were
determined after 72 hours as described above.
Flow cytometry analysis
Stimulated PBMC were washed and incubated for 30 minutes
on ice with directly conjugated antibodies (CD3: SK7, R&D
Systems; CD45: T29/33, BD Biosciences; HLA-DR: TU36, Life
technologies) in combination with a dead cell marker (Live/Dead
Fixable near IR; Molecular Probes). Analyses were done using a
Beckton Dickinson LSRII SORP flow cytometer and FlowJo
9.5.3.
Statistical evaluation
Data were analyzed by GraphPad Prism version 4.0 for
Windows (GraphPad software). Two-sided Mann-Whitney U test
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or Fisher’s exact test were used for comparison between two
groups. Comparisons between multiple groups were done using
ANOVA and Dunn’s multiple comparison test. Differences were
considered significant when p,0.05.
Results
Distinct functional phenotypic profiles of clinical S.
aureus strains
A proliferation assay was employed in which PBMC were
exposed to bacterial supernatants prepared from CA S. aureus
strains. The strain collection included CA MRSA and MSSA
strains of varying ST types, agr types and toxin gene profile
isolated from patients or colonized individuals (Table 1). All
strains, except two (strains Sa159 and Sa160), harbored superan-
tigen encoding genes (Table 1). To confirm that the genes were
expressed during in vitro culture, the bacterial supernatants were
analyzed for toxin content using a customized luminex assay. Due
to technical limitations only a selected set of exotoxins, i.e. a-toxin,
SEB and TSST-1, were included for which the protein detection
concurred with the toxin gene profile of respective strain (Table 1).
PBMC from four different donors were stimulated with serial
dilutions of the bacterial supernatants and proliferative responses
assessed (Figure 1A). This assay is commonly used to functionally
assess superantigen-mediated proliferation, but the response will
be influenced by the presence of cytotoxins targeting PBMC.
Accordingly, supernatants prepared from the different S. aureus
strains induced starkly different (p,0.0001) and highly reproduc-
ible response profiles (Figures 1A, 1B). While some strains induced
consistently high proliferative responses at all dilutions (1:50, 1:100
and 1:1000) of the bacterial supernatants (denoted as a prolifer-
ative profile) (Figures 1A, 1B), other strains induced proliferation
only at the highest dilution (1:1000) of bacterial supernatants
(Figures 1A, 1B). Thus, demonstrating that the supernatants
contain superantigens that trigger proliferation, but this activity
is masked in more concentrated supernatants from certain strains,
potentially through toxin-mediated cytotoxicity.
To investigate this further, proliferation was assessed following
stimulations of PBMC with the polyclonal T cell activator PHA in
combination with supernatants displaying a proliferative or
cytotoxic profile (Figure 1C). Using the 1:50 dilutions of bacterial
supernatants, the PHA-response was completely abolished by the
cytotoxic supernatants, whereas augmented by the proliferative
supernatants (Figure 1D). To directly assess whether bacterial
supernatants were cytotoxic, flow cytometry analysis was applied
on cells stimulated with supernatants and subsequently stained
with a dead cell marker in combination with antibodies directed
towards defined cell markers. PBMC stimulated with a prolifer-
ative supernatant showed a relative expansion of the T cell
population similar to that seen for PHA (Figure 1E). Notably,
stimulation with a cytotoxic supernatant resulted in extensive cell
death as almost all cells stained positive for the dead cell marker
(Figure 1E). As shown in Table 1, cell death was significantly more
pronounced among cells exposed to cytotoxic, as compared to
proliferative, supernatants (mean % of cells staining positive for
dead cell marker: 96.3% and 33.2% for cytotoxic and proliferative
supernatants, resp.; p,0.001).
The two functional response profiles were found in both
colonizing as well as patient isolates and there was no significant
association between functional profile and ST-type/clonal com-
plex or MRSA/MSSA type (Table 1). In contrast, an association
with agr type was evident, and agr II and agr III strains had
predominantly a proliferative profile whereas agr I and IV strains
were cytotoxic (p,0.015) (Figure 1F). As these analyses were
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conducted on a highly heterogeneous strain cohort, we expanded
the analyses to include a more homogenous strain cohort collected
from patients with CA S. aureus pneumonia. Also in this cohort, a
similar association with agr I and IV being significantly more
cytotoxic than agr II or III was noted (p,0.034) (Figure 1G).
High a-toxin expression is linked to the cytotoxic profiles
Quantitation of the cytotoxins a-toxin and PVL revealed that
the cytotoxic supernatants had significantly higher levels of a-toxin
than the proliferative, regardless of whether the strains were
collected from patients, colonized individuals, or CA pneumonia
(p,0.002) (Figure 2A). In contrast, there was no correlation
between the response profile and PVL expression (Figure 2B)
which is in line with the reported lack of susceptibility of PBMC to
PVL [32]. In agreement with the data in Figure 1F demonstrating
that different agr types are linked to either proliferative or
cytotoxic profiles, significantly higher amounts of a-toxin were
found in strains belonging to the cytotoxic agr type I and IV, as
compared to the proliferative agr type II and III strains (p,0.05)
(Figure 2C). In this context, no association between PVL levels
and specific agr types was seen (Figure 2D). Also, expression data
on the psm-a gene revealed no difference between strains eliciting
either response profile (data not shown).
These data implied that a-toxin is a main mediator of the noted
cell death in PBMC. To further test this, PBMC were stimulated
with PHA in combination with purified a-toxin revealing a clear
dose response pattern where increasing amounts of a-toxin
resulted in reduced proliferation (Figure 3A). Furthermore,
supplementing a proliferative (Sa1437) or a cytotoxic (Sa368) S.
aureus supernatant with purified a-toxin, resulted in a switch to a
cytotoxic response both at the 1:1000 and 1:50 dilutions for the
proliferative strain and an increased cytotoxic response at the
1:1000 dilution for the cytotoxic strain (Figure 3B). Further
support for an a-toxin-mediated effect was provided by using a
strain of the USA300 lineage (LUG2012), which belongs to the
cytotoxic agr type I and produces high levels of a-toxin (a-toxin
83 mg/ml, PVL 14 mg/ml), and its isogenic mutants for PVL (a-
toxin 54 mg/ml, PVL 0 mg/ml) and a-toxin (a-toxin 0 mg/ml,
PVL 11 mg/ml). The USA300 and the PVL-deficient mutant both
showed a cytotoxic profile, whereas the a-toxin mutant showed a
proliferative response profile (Figure 3C). Also when PBMC were
stimulated with PHA in combination with these supernatants a
reduction of PHA-induced responses was noted in the presence of
supernatants from USA300 and the PVL-deficient mutant
(Figure 3D). In contrast, the a-toxin mutant supernatant resulted
in an augmentation of the PHA-induced response (Figure 3D).
Flow cytometry analysis further confirmed a potent cytotoxic effect
of USA300 and the PVL-deficient mutant supernatants (97.2%
and 85.8% dead cell marker positivity, resp.), whereas the a-toxin
mutant supernatant had limited cytotoxicity (20.4% dead cell
marker positivity). It should be noted that although the superna-
tant of the a-toxin mutant elicited a proliferative response at all
dilutions tested, the proliferative response increased with more
diluted supernatants (Figure 3C); thus, indicating that there are
inhibitory factors, other than a-toxin, present in the USA300
supernatant. Other cytotoxins tested, including purified PVL,
PSM-a3 and d-toxin alone or in combination with PHA did not
elicited any cytotoxic or proliferative responses in PBMC
(Figure 3E).
IVIG inhibition of toxin mediated responses in PBMC
Studies have demonstrated the presence of antibodies against
defined S. aureus virulence factors, including a-toxin, PVL and
superantigens, in intravenous polyclonal immunoglobulin (IVIG)
preparations [33–37]. Here we tested whether IVIG could inhibit
the toxin-mediated functional response profiles, in particular the
cytotoxic effect associated with high a-toxin levels. To this end,
PBMC were stimulated with PHA and different concentrations of
purified a-toxin in the presence or absence of IVIG. We found a
clear dose response of IVIG-mediated inhibition of a-toxin
cytotoxicity, evident by increased proliferative responses (Fig-
ure 4A). At the lowest concentration of a-toxin (60 ng/ml), a
significant inhibition was achieved with 0.1 mg/ml IVIG
(p= 0.05) while at the highest concentration of 480 ng/ml of a-
toxin significant neutralization was achieved only at concentra-
tions .1.0 mg/ml of IVIG (p= 0.034) (Figure 4A). Similarly we
found that IVIG was able to inhibit both the proliferative as well as
the cytotoxic responses elicited by superantigens and cytotoxins
present in S. aureus culture supernatants (Figure 4B).
Discussion
In this study we demonstrate that CA S. aureus strains with
distinct toxin profiles exhibit stable robust phenotypic profiles
evident by their ability to elicit either a proliferative or cytotoxic
response profile in human PBMC. All experiments were done
using bacterial supernatants containing superantigens and cyto-
toxins secreted by the strains. The data shows that the vast
majority of strains elicit superantigenic activity as demonstrated by
the induction of proliferative responses in PBMC. However, this
Figure 1. Proliferative or cytotoxic responses elicited by S. aureus strains. Human peripheral blood mononuclear cells (PBMC) isolated from
healthy donors were stimulated with dilution series (1:1000 (open), 1:100 (stripped) and 1:50 (filled) bars) of bacterial supernatants prepared from
overnight cultures of S. aureus strains. Proliferative responses were determined by 3H-thymidine uptake and are presented as mean counts per
minute6 SD. The supernatants induced either a proliferative or cytotoxic response profile. A cytotoxic profile was assigned when strains did not elicit
a proliferative response in the more concentrated supernatants but only in the most diluted samples. A) Shows the response of a representative
proliferative and cytotoxic supernatant in separate experiments using cells from four healthy donors. B) Scatter plot of proliferative responses
induced by bacterial supernatants with a proliferative or a cytotoxic profile. Mean values of four different experiments are shown for dilutions 1:1000
(filled symbols) and 1:50 (open symbols). C) Bacterial supernatants with proliferative or cytotoxic profiles were found among both patients (n = 20)
and colonized individuals (n = 17). The figure shows proliferative responses (mean 6 SD) of one representative, out of five, experiments using cells
from different donors stimulated with dilution series (1:1000 (open), 1:100 (stripped) and 1:50 (filled) bars) of bacterial supernatants. D) To confirm a
cytotoxic effect, proliferative responses were assessed in cells stimulated with PHA alone (the dashed line shows the average PHA response) or in
combination with supernatants (proliferative and cytotoxic; dilution 1:50 (filled) bars). The figure shows one representative of three experiments
using cells from different donors. E) Flow cytometry analysis on PBMC stimulated with PHA and bacterial supernatants (1:50 dilution). Total PBMC
were gated based on CD45 expression and CD45 positive cells were further analysed for dead cell marker (DCM, Y axis) and CD3 (X axis) positivity.
The figure shows one representative of three individual experiments using cells from different donors. F) Relation between agr types and proliferative
(black bars) or cytotoxic (white bars) community S. aureus strains collected from colonizing individuals (n = 17) or patients with infections (n = 20) in
India. G) Relation between agr type and proliferative or cytotoxic profiles elicited by community-acquired (CA) pneumonia patients (n = 31). Statistical
significant differences were determined by use of the two-sided Mann Whitney test and Fisher’s exact test with two sided p value and p values are
indicated in the figure.
doi:10.1371/journal.pone.0106107.g001
Staphylococcal Phenotypic Response Profiles
PLOS ONE | www.plosone.org 6 August 2014 | Volume 9 | Issue 8 | e106107
response was masked in cytotoxic strains due inhibitory/cytotoxic
factors present in the supernatants. This illustrates the relevance of
using such a mixture of secreted factors from clinical isolates,
which allows simultaneous analyses of the combined activity of
toxins and which more closely reflects what the patients are
exposed to. The PBMC assay provided an efficient tool to assess
both superantigenic and cytotoxic effects; thereby allowing for
identification of distinct phenotypic response profiles among CA S.
aureus isolates. However, it should be noted that this assay
involves only PBMC and hence, excludes effects of pore-forming
toxins, such as PVL, LukDE and LukAB, that targets cell
populations which are either missing or represent a minor subset
in PBMCs [32,38,39]. Therefore, future studies should include
also other clinically relevant cells, such as neutrophils, that are
highly susceptible to the above mentioned cytotoxins.
Our findings demonstrated a striking association between high
a-toxin levels and a cytotoxic phenotypic profile of the S. aureus
strains. Supernatants that displayed a cytotoxic profile had in
average 20-fold higher a-toxin levels than the proliferative
supernatants (p,0.0001). Furthermore addition of purified a-
toxin to either bacterial supernatants or to PHA resulted in a dose-
dependent transition from proliferative to cytotoxic response
profiles. Also, a USA300 a-toxin deficient mutant revealed a
proliferative profile in contrast to the wildtype USA300 strain that
was distinctly cytotoxic. As a vast majority (29/33) of the cytotoxic
supernatants contained $225 ng/ml a-toxin, whereas all prolif-
erative supernatants had levels below 221 ng/ml (in the 1:50
dilutions), we speculate that there might be a critical a-toxin
concentration determining cytotoxic responses in PBMC. This
underscores the value of quantifying the levels of toxins produced
and secreted by the strains as this seems to dramatically influence
the cellular responses and potentially virulence.
Similarly, a significant association between response profiles, a-
toxin levels and the agr type of the strain was noted. Significantly
increased a-toxin levels were found in the cytotoxic agrI and IV
types, as compared to the proliferative agrII and III strains. The
complexity of agr regulation of S. aureus virulence factors was
emphasized in the report by Geisinger et al [19] in which protein
A, a-toxin, PVL and TSST-1 were tested in congenic strains each
harboring a unique agr allele (I–IV). They found significant
variation in the kinetics and degree of the agr signal resulting in
differential induction of specific virulence factors. Of special
interest, is their finding that agr I and IV are the earliest and
strongest, followed by agr II and III, which is the same
hierarchical order as we report here in regards to cytotoxicity.
The molecular basis for the noted association between toxin
Figure 2. Levels of alpha-toxin expression correlate with cytotoxic profile and agr types. Amounts of alpha-toxin (a-toxin) (A) and Panton
Valentine Leukocidin (PVL) (B) were determined by ELISA in the S. aureus bacterial supernatants (1:50 dilutions) having either a cytotoxic (C; open
symbols) or a proliferative (P; filled symbols) response profile. Supernatants prepared from isolates collected from colonized individuals (n = 17),
patients (n = 17), or a confirmatory cohort of CA pneumonia (n = 31) are shown. Association between amount of a-toxin (C) and PVL (D) in the S.
aureus bacterial supernatants (1:50 dilutions; n = 65) with their respective agr types (agr I and IV, open symbol; agr II and III, filled symbol). Statistical
significant differences were determined by use of the two-sided Mann Whitney test or with ANOVA and Dunn’s multiple comparison test for
comparisons of multiple groups and p values are indicated in the figure.
doi:10.1371/journal.pone.0106107.g002
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production and agr types translating into distinct response profiles
has yet to be determined but could possibly be linked to varying
levels of secreted auto inducing peptides (AIP). Another possibility
is that the AIP-AgrC interaction kinetics may vary between the
proliferative and cytotoxic isolates, as previous studies
[15,17,18,40] have shown that agr I and IV AIPs share almost
identical primary sequence with only one amino acid difference
whereas agr II and III AIPs show greater variations in their
primary sequence.
Another interesting aspect is the potential link between genetic
background, agr type and disease manifestation [18,41]. Although
the link is far from exclusive, agr IV are often emphasized as a
disease-related isolate [42,43]. Furthermore Jarraud et al [41]
reported a predominance of agr II and III in TSST-1 mediated
TSS and scarlet fever (90–94%, respectively). Here we report
Figure 3. Alpha-toxin mediates cytotoxicity in PBMC. A) Proliferation assay using human PBMC stimulated with PHA alone or in the presence
of different concentrations of a-toxin. Proliferative responses were determined by 3H-thymidine uptake and are presented as mean counts per
minute 6 SD. Mean values of four different experiments from different donors are shown. B) Inhibition of PHA-induced and bacterial supernatant-
induced proliferation of PBMCs by addition of increasing concentrations of a-toxin (60 to 480 ng/ml). The figure shows one representative of two
experiments using cells from different donors. C) Proliferation assay using cells from two donors stimulated with different dilutions (1:1000 (open),
1:100 (stripped) and 1:50 (filled) bars) of supernatants prepared from USA300 (LUG2012), and its isogenic mutants of PVL (DlukSF-PV) and a-toxin
(Dhla). D) Proliferative responses assessed in cells stimulated with PHA alone or in combination with indicated supernatants at dilutions 1:1000 (open)
and 1:50 (filled) bars. The figure shows experiments using cells from two donors. E) PBMC were stimulated with increasing concentrations of PVL, PSM
a3 and d-toxin at indicated concentrations (mg/ml) alone and in combination with PHA. Statistical significant differences were determined by Fisher’s
exact test with two sided p value and p value is indicated in the figure.
doi:10.1371/journal.pone.0106107.g003
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distinct phenotypic response profiles elicited by clinical CA S.
aureus isolates, which are determined by the combined action of
a-toxin and superantigens, and the data shows a striking
association to specific agr types, such as the agr II and III that
demonstrated a superantigen-mediated proliferative profile where-
as agr I and IV were cytotoxic. Whether these phenotypic
response profiles reflect specific pathotypes that contribute to
distinct disease manifestations can at present time only be
speculated upon and can only be addressed by the use of large
well-defined clinical cohorts. For instance, the course of bacter-
emia, toxic shock syndrome and/or necrotizing infections of the
skin and lung might be connected to a specific ratio of
superantigenic activity versus cytotoxicity, which would determine
the overall biological effect on patients’ immune cells. However,
we fully appreciate the complexity of identification of pathotypes
dictated by toxin-mediated cellular responses. Clinical manifesta-
tions and outcome will depend on a variety of factors including
among others varying host susceptibility at both the cellular and
genetic level as well as site of infection. In addition, patients can
present with both necrotizing infections and severe sepsis/septic
shock, which raises the currently unexplored question of expres-
sion levels and effects of superantigens and cytotoxins systemically
and locally. Nevertheless, identification of specific pathotypes
would be of great clinical value as it enables recognition of risk
patients and allows for epidemiologic surveillance.
Although clinical data are limited, IVIG has been proposed as
adjunctive therapy in fulminant invasive S. aureus infections and
the mechanistic action suggested to involve neutralizing antibodies
against superantigens [33,35], PVL [37] and a-toxin [34]. Here
we found that addition of IVIG to PBMC cultures efficiently
inhibited both a-toxin-mediated cytotoxicity as well as superan-
tigen-mediated proliferation at physiological concentrations. Thus,
our data support a beneficial role of IVIG that through its broad
Figure 4. Inhibition of a-toxin and staphylococcal supernatant mediated cytotoxicity and proliferation of PBMC by IVIG. A)
Neutralization of a-toxin induced cytotoxicity of PBMC by different concentrations of IVIG. PBMC were stimulated with PHA with increasing
concentrations of a-toxin (60 to 480 ng/ml) in the presence or absence of IVIG (0.1 to 2.5 mg/ml, as indicated). The dashed line indicates the mean
PHA-induced proliferative response. B) Proliferative responses induced by bacterial supernatants from both proliferative and cytotoxic strains
(dilutions 1:1000 and 1:50) in the presence or absence of different concentrations of IVIG (0.1 to 2.5 mg/ml, as indicated). 3H-thymidine uptake after
72 hours of culture is presented as mean counts per minute6 SD. The figure shows one representative of two experiments using cells from different
donors.
doi:10.1371/journal.pone.0106107.g004
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spectrum of antibodies can prevent toxin-mediated damage,
including both excessive proliferation as well as cytolytic events.
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